Introduction
Leading global contract research and manufacturing organization extended its long-term collaboration with a major pharmaceutical company until 2035, covering research, development, manufacturing, and clinical trial services worldwide.
Also Read: ITCONS E-Solutions bags ₹6.7 crore contract from Bank of Maharashtra
Share price movement of Syngene International
On January 19, 2026, Syngene International Ltd opened at ₹621.25, down 0.94% from its previous close of ₹627.15. The stock hit a high of ₹628.05 (0.16%) and a low of ₹620.00 (1.12%). By 10:50 AM, it traded at ₹628.05, a 0.14% rise, with a market capitalisation of ₹25,306.61 crore.
Syngene Extends Bristol Myers Collaboration
Syngene International announced the extension of its strategic collaboration with Bristol Myers Squibb until 2035. The agreement covers research, drug development, pharmaceutical manufacturing, clinical trials, and IT services across the lifecycle.
The collaboration, started in 1998, led to the Biocon Bristol Myers Squibb R&D Center (BBRC) in 2009. The center supports target identification, lead discovery, optimization, and clinical biomarker development.
BBRC houses around 700 Syngene scientists working with Bristol Myers Squibb globally. The center contributes to discovery, preclinical development, and patent filings in cardiovascular, fibrosis, immunology, and oncology therapeutic areas.
Stock performance of Syngene International for Period of 1 week, 6 months, and 1 year
Syngene International Ltd fell 1.06% over the past week, declined 7.88% in the past 6 months, and dropped 23.5% over the past 1 year.
Also Read: Sun Pharma launches UNLOXCYT for advanced skin cancer treatment
Shareholding pattern of Syngene International
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 52.70% | 52.70% | 52.70% |
| FII | 16.30% | 16.50% | 19.50% |
| DII | 24.60% | 24.10% | 21.50% |
| Public | 6.10% | 6.50% | 6.00% |
About Syngene International
Syngene International Ltd (NSE: SYNGENE) is a global R&D and manufacturing services company serving pharmaceuticals, biotech, consumer goods, and chemicals with 8,200 employees and 2.5 mn sq. ft facilities.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Syngene International Ltd share price rising today?
A: Syngene International extends collaboration with Bristol Myers Squibb until 2035, covering research, drug development, manufacturing, and clinical trial services.
Q: What is Syngene International Ltd’s main business focus?
A: Syngene International focuses on research, development, and manufacturing services for pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals.
Q: What is the 52-week high and low of Syngene International Ltd stock?
A: Syngene International stock has a 52-week high of ₹862.00 and a 52-week low of ₹598.55.
